Mali Barbi, MD, MS, on Endometrial Cancer: Data in dMMR Disease and B7-H4 ADCs for Advanced Disease

June 08, 2026 By The ASCO Post Staff

Mali Barbi, MD, MS, of Northwell Health Cancer Institute Center for Women's Cancer, discusses durable survival benefits shown in the NRG-GY018 trial with pembrolizumab and the RUBY trial with dostarlimab for patients with mismatch repair–deficient (dMMR) endometrial cancer. In addition, B7-H4 antibody-drug conjugates such as puxitatug samrotecan are emerging as options for relapsed/metastatic disease.

Related Content